Aurobindo Pharma has inked a pact to acquire Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million (around Rs 969 crore).
The company has inked a binding agreement through its wholly-owned subsidiary Agile Pharma BV Netherlands to acquire Generis Farmaceutica for a total consideration of €135 million, Aurobindo Pharma said in a statement today.
Generis produces and sells pharma products in Portugal.
“The acquisition of Generis, by leveraging its strong portfolio and unrivalled brand recognition, will allow us to establish ourselves as the top generics player in the Portuguese market,” Aurobindo SVP-European Operations V Muralidharan said.
The combined entity will benefit from a robust pipeline covering all major molecules coming off patent in the next five years, he added.
“This acquisition coupled with our past acquisition activity underlines our commitment to focus on growth initiatives in European markets and will be a a key driver of growth for the future,” Muralidharan said.
Closing of the transaction, however, is conditional on obtaining necessary approvals from the Portuguese authorities.
The acquisition deal includes the Generis’s manufacturing facility in Amadora, Portugal which has a capacity to produce 1.2 billion tablets/capsules/sachets annually.
Generis CEO Paulo Lilaia said the company would benefit immensely from Aurobindo’s vertical integration and strong product pipeline.
“Our large portfolio along with our unmatched commercial presence in Portugal will allow Aurobindo to consolidate its market position in Portugal,” he added.
With the latest acquisition, Aurobindo will now have a portfolio of 271 products in the European nation.
The Hyderabad-based firm has been steadily expanding its European footprint since 2006. In 2014, it had acquired Actavis’s commercial operations in seven Western European countries.